Q-line Biotech
Spreading Healthiness!

Date: September 02, 2026

To,
Corporate Relationship Department
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G, Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051

Company Code: QLINE

Sub: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Amended and Restated License Agreement with Boule Medical AB, Sweden.

Dear Sir/Madam,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby submit the disclosure regarding the Amended and Restated License Agreement entered into by Q-Line Biotech Limited ("Q-Line") with Boule Medical AB, Sweden ("Boule").

The Agreement has been executed by mutual consent of the Parties to revise and consolidate the existing licensing and technology transfer arrangements, with a view to enhancing market outreach, deeper market penetration and sustainable long-term growth.

A key commercial benefit under the revised arrangement is the reduction of license/royalty payable by Q-Line to Boule by 25%, with the revised license/royalty terms being effective from 01st July 2026, along with other mutually agreed commercial revisions.

The detailed Press Release containing the material details of the arrangement is enclosed herewith.

The above information is also available on the Company's website at www.qlinebiotech.com.

You are requested to kindly take the same on record.

For Q-Line Biotech Limited

SAURABH GARG
Digitally signed by SAURABH GARG
Date: 2026.09.02 17:16:29 +05'30'

Saurabh Garg
Chairman and Managing Director
DIN: 02891621

Q-line Biotech
Spreading Healthiness!

PRESS RELEASE

Q-Line Biotech Limited Strengthens Strategic Partnership with Boule Medical AB, Sweden
Lucknow | September 02, 2026

Q-Line Biotech Limited ("Q-Line" or "the Company") has entered into an Amended and Restated License Agreement with Boule Medical AB, Sweden ("Boule"), by mutual consent of both Parties, to revise and consolidate the existing technology transfer and licensing arrangements relating to diagnostic reagents, consumables and haematology analyser platforms.

25% Reduction in License/Royalty Cost

A key commercial outcome of the revised arrangement is a 25% reduction in the license/royalty payable by Q-Line to Boule, with the revised license/royalty terms being effective from 01st July 2026. The revised commercial framework is expected to improve the Company's cost efficiency and competitiveness, particularly in price-sensitive government and institutional markets.
The revised arrangement is designed to create a mutually beneficial and win-win commercial proposition for both Parties. While the reduction in license/royalty cost will enhance Q-Line's competitiveness and ability to pursue larger market opportunities, the resulting potential increase in market outreach, product adoption, installed base and recurring reagent volumes is expected to create long-term growth opportunities for both Q-Line and Boule.

Expanding Market Outreach and Penetration

The revised arrangement has been mutually agreed with the objective of enhancing market outreach, achieving deeper market penetration and supporting sustainable long-term growth in India, with potential opportunities for overseas markets.
The Agreement also provides for rationalised minimum purchase commitments, revised instrument license fees, adjustment of advance royalties, extended payment terms and volume-linked commercial benefits, providing Q-Line with greater flexibility to pursue larger market opportunities.
The revised framework is expected to support the Company's strategy of expanding its installed base of diagnostic instruments and recurring reagent business, while enabling more competitive participation in government and institutional opportunities.

Management Commentary

Mr. Saurabh Garg, Managing Director, Q-Line Biotech Limited, said:
"The amended agreement with Boule marks an important step in strengthening our technology partnership and creating a more sustainable and mutually beneficial commercial framework. The 25% reduction in license/royalty costs will enhance our competitiveness and provide greater flexibility to pursue larger market opportunities.
We believe this is a win-win arrangement for both Parties. Greater competitiveness for Q-Line can translate into wider market outreach, deeper penetration, higher instrument placements and increased recurring reagent opportunities, thereby creating sustainable long-term value for both Q-Line and Boule."
The Agreement has an initial term of five (5) years and may be further extended for up to five (5) years by mutual written consent of the Parties.

SAURABH GARG
Digitally signed by SAURABH GARG
Date: 2026.09.02 17:16:45 +05'30'